A pilot study shows that immunotherapy may enable stimulation of egg maturation in women with premature menopause. Three out of ten women gave birth to healthy babies following the treatment.
A study from the University of Calgary shows that removing a single gene makes colon cancer cells a target for immunotherapy — a fundamental breakthrough.
Radiopharmaceutical therapy has already transformed care for neuroendocrine tumors and prostate cancer, but other tumor types still lack targeted treatment options. A new approach could change this.
For patients with knee osteoarthritis, for whom injections no longer provide sufficient relief, but joint replacement is also not an option, a minimally invasive treatment might offer an alternative.
A promising technology enables deep brain stimulation without the need to surgically implant electrodes. This could pave the way for its use in the treatment of neurological and psychiatric disorders.
A new type of peptide receptor radionuclide therapy (PRRT) appears to be safe in metastatic neuroendocrine tumor patients who have exhausted conventional treatment options.
Researchers have reported results from a first-in-human trial evaluating a novel cell-based platform for localized delivery of interleukin-2 (IL-2) in patients with advanced ovarian cancer.
A CRISPR-based tool called Cas12a2 can selectively eliminate cancer and virus-infected cells based on their RNA signature – with high precision and no off-target effects.
Researchers are developing nanozymes to improve treatment of aggressive brain tumours. The tiny particles can be activated by near-infrared light and applied directly during surgery.
Now, a new study identified a gene therapy for individuals with cystic fibrosis (CF) caused by a specific mutation and for whom there was no treatment available until now.
Most children with a broken wrist can be treated without surgery, a major trial finds, suggesting that a cast-first approach delivers similar long-term recovery while reducing risks and costs.
A multidisciplinary team of pathologists, oncologists and biologists has discovered a new biomarker to determine whether immunotherapy may work in people with colon and rectal cancer.
A clinical trial has shown that post-thrombotic syndrome — a common and often painful complication after deep vein thrombosis — can be effectively treated with a minimally invasive procedure.
Why do some cancer cells develop treatment resistance? The answer may lie in hidden “storage hubs” inside tumour cells, which create uneven drug exposure across tumours, according to new research.
About 50% of triple-negative breast cancer (TNBC) patients develop resistance to therapy, significantly reducing the chances of survival. Researchers found there is more than one way this can happen.
Although tumours may at first shrink under therapy, they often regrow or even become resistant. A new study suggests switching to a second treatment while the tumour is still responding to the first.
Even after a blood clot is removed from a large brain artery via thrombectomy, administering the thrombolytic drug alteplase to the area may improve stroke recovery, a new trial from Spain shows.
A new European study suggests that PFA may offer hospitals a way to treat atrial fibrillation more efficiently – with shorter procedures and lower costs than established methods.
Should younger and older people receive different treatments for the same infection? New research suggests that age-specific treatments may be necessary in ongoing antibiotic resistance crisis.
